ALung brings in $12M to move forward with approval of its artificial lung
ALung Technologies Inc. has secured $12 million from investors. The Pittsburgh-based medical device company is working toward U.S. regulatory approval of its artificial lung.
ALung secures $10M ahead of artifical lung system’s launch in Germany
ALung Technologies Inc. has raised a $10 million series B round in preparation for a product launch of its Hemolung oxygen-delivery device in Germany this year, the Pittsburgh Tribune-Review is reporting. MedCity News reported back in December that the medical device company had already raised $6.6 million and filed for the CE Mark. The Hemolung […]
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
ALung planning European launch of artificial lung system
ALung Technologies is targeting a $10 million series B round of investment for the European launch of its respiratory assistance system that removes carbon dioxide from a patient’s blood while directly infusing the blood with oxygen. The company is already most of the way there, having just closed on $6.6 million and having received commitments […]
Pittsburgh’s ALung raises $14M for artificial lung system
More than 100 angel investors helped ALung Technologies Inc. in Pittsburgh, Pennsylvania, to a $14 million fundraising round, according to Pop City. ALung will use the latest investor capital to pay for ongoing clinical trials of its Hemolung Respiratory Assist System -- a kind of artificial lung that removes carbon dioxide directly from a patient's blood while infusing it with oxygen.
ALung Technologies adds $2.8M in equity to anticipated $10M round
Respiratory-assistance company ALung Technologies Inc. has added $2.8 million in equity to what it hopes will be a $10 million round of investment funding, according to a Securities and Exchange Commission filing. The latest fundraise brings to $6.1 million the amount that ALung has raised since February. The funding includes contributions from 22 investors, according […]
Pittsburgh’s ALung grabs $3.3M for artificial breathing system
ALung Technologies Inc. has raised $3.3 million in equity as part of an intended $10 million offering. The company is developing a respiratory-assistance system it calls the Hemolung, which delivers oxygen directly into the blood using a catheter into the femoral or jugular vein.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Pittsburgh’s ALung raises $2.5 million for clinical trials
The company is developing its Hemolung System, which delivers oxygen directly into the blood using a catheter into the jugular vein. Later this year it will start a five-patient human trial in India and a 20-patient trial in Germany.